Efficacy and Safety of Tabelecleucel▼ in Epstein-Barr Virus-Associated Relapsed/Refractory Post-Transplant Lymphoproliferative Disease: Update From the Phase III ALLELE Study

This presentation was part of the ‘CAR-T and other cell therapies’ oral presentation session of the EBMT 51st Annual Meeting, held in Florence, Italy on 2nd April. Sridhar Chaganti, Consultant Haemato-oncologist at University Hospital Birmingham, UK, presented updated results from the ongoing Phase III ALLELE trial evaluating the safety and efficacy of tabelecleucel, an off-the-shelf allogeneic T cell immunotherapy, in relapsed/refractory Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease (PTLD). In this latest analysis in a total of 75 patients, the overall response rate (ORR) in recipients of hematopoietic cell transplant (HCT) or solid organ transplants (SOT) was 50.7%, with median response duration of 23 months and a 12-month overall survival (OS) rate of 78.7% in responders. Tabelecleucel was well tolerated, with no cases of tabelecleucel-related graft-versus-host disease or organ rejection reported.